Literature DB >> 8057119

Surgical treatment of brain metastases of lung cancer: retrospective analysis of 89 cases.

H Nakagawa1, Y Miyawaki, T Fujita, S Kubo, K Tokiyoshi, K Tsuruzono, K Kodama, M Higashiyama, O Doi, T Hayakawa.   

Abstract

The records of 89 patients who underwent surgery for solitary or multiple parenchymal brain metastases of lung cancer at the Osaka Center for Adult Diseases between 1978 and 1990 were reviewed with follow up until March 1992. The aim of this retrospective analysis was to identify prognostic features that were associated with a favourable outcome. The benefits of brain tumour surgery were evaluated in terms of the cause of death (brain metastasis, tumour in another organ, or treatment related) as well as the postoperative changes in functional state indicated by the Karnofsky scale. The overall mean survival time was 11.6 months, and the one and two year survival rates were 24% and 8%. The brain lesion itself was the cause of death in only 19% of the patients; the other 81% died of systemic disease. Functional state improved after surgical excision of the brain tumour in 36%, remained unchanged in 53%, and worsened in 11%. These data suggest that surgical intervention is beneficial for patients with parenchymal brain metastases. Variables significantly associated with a favourable prognosis included surgical excision of the primary lesion, adenocarcinoma as the histological diagnosis, the use of adjuvant treatment, especially chemotherapy, a preoperative score of over 80% on the Karnofsky scale, and metastasis confined to the brain with no extracranial metastatic foci or residual primary tumour. Additional but non-significant contributors to a good prognosis included age under 65 or 70 years, early tumour stage (stage 1), curative lung cancer surgery, a single metastatic brain tumour (v multiple lesions), a solid tumour (v cystic), and a supratentorial location of the brain metastasis. The disease free interval and the cerebrospinal fluid cytology were not significant prognostic factors. On the basis of these findings, it is concluded that the surgical removal of brain metastases of lung cancer should be undertaken if the primary tumour has already been removed whether or not there are extracranial metastases, and that postoperative chemotherapy should generally be given.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057119      PMCID: PMC1073080          DOI: 10.1136/jnnp.57.8.950

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  Surgical management of metastatic tumors.

Authors:  J Ransohoff
Journal:  Semin Oncol       Date:  1975-03       Impact factor: 4.929

2.  Phase II study of high-dose cis-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer.

Authors:  E S Casper; R J Gralla; D P Kelsen; E Cvitkovic; R B Golbey
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

3.  High-dose cisplatin for lung cancer.

Authors:  V K Bhuchar; V J Lanzotti
Journal:  Cancer Treat Rep       Date:  1982-02

4.  Results of operative treatment of intracranial metastatic tumors.

Authors:  K R Winston; J W Walsh; E G Fischer
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

5.  Single metastasis to the brain. Surgical treatment in 122 consecutive patients.

Authors:  K T White; T R Fleming; E R Laws
Journal:  Mayo Clin Proc       Date:  1981-07       Impact factor: 7.616

6.  The natural history of breast cancer patients with brain metastases.

Authors:  A DiStefano; Y Yong Yap; G N Hortobagyi; G R Blumenschein
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

Review 7.  Brain metastasis: current status and recommended guidelines for management.

Authors:  P Black
Journal:  Neurosurgery       Date:  1979-11       Impact factor: 4.654

8.  High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).

Authors:  R De Jager; E Longeval; J Klastersky
Journal:  Cancer Treat Rep       Date:  1980

9.  Surgical treatment of single brain metastasis: factors associated with survival.

Authors:  J H Galicich; N Sundaresan; E Arbit; S Passe
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

10.  cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects.

Authors:  H Nakagawa; T Fujita; S Izumimoto; Y Miyawaki; S Kubo; Y Nakajima; K Tsuruzono; K Kodama; M Higashiyama; O Doi
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

View more
  6 in total

1.  The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy.

Authors:  C Y Hsiung; S W Leung; C J Wang; S K Lo; H C Chen; L M Sun; F M Fang
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

2.  Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.

Authors:  A Ali; J R Goffin; A Arnold; P M Ellis
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

3.  Recursive partitioning analysis classification and graded prognostic assessment for non-small cell lung cancer patients with brain metastasis: a retrospective cohort study.

Authors:  Cai-Xing Sun; Tao Li; Xiao Zheng; Ju-Fen Cai; Xu-Li Meng; Hong-Jian Yang; Zheng Wang
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

4.  Surgical resection of brain metastases from lung cancer.

Authors:  R J Andrews; D S Gluck; R H Konchingeri
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Characteristics of brain metastases from esophageal carcinoma.

Authors:  Takahiro Yamamoto; Jun-Ichiro Kuroda; Tatsuya Takezaki; Naoki Shinojima; Takuichiro Hide; Keishi Makino; Hideo Nakamura; Shigetoshi Yano; Toru Nishi; Jun-Ichi Kuratsu
Journal:  Surg Neurol Int       Date:  2014-09-22

6.  Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.

Authors:  Chunhua She; Ruixia Wang; Changhong Lu; Zengfeng Sun; Peng Li; Qiang Yin; Qun Liu; Peng Wang; Wenliang Li
Journal:  Thorac Cancer       Date:  2018-11-28       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.